This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Coherus BioSciences stock | $18.02

Own Coherus BioSciences stock in just a few minutes.

Posted

Fact checked

Coherus BioSciences, Inc is a biotechnology business based in the US. Coherus BioSciences shares (CHRS) are listed on the NASDAQ and all prices are listed in US Dollars. Coherus BioSciences employs 306 staff and has a trailing 12-month revenue of around USD$487.4 million.

How to buy shares in Coherus BioSciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Coherus BioSciences. Find the stock by name or ticker symbol: CHRS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Coherus BioSciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$18.02, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Coherus BioSciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Coherus BioSciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Coherus BioSciences share price

Use our graph to track the performance of CHRS stocks over time.

Coherus BioSciences shares at a glance

Information last updated 2020-10-20.
Latest market close USD$18.02
52-week range USD$10.8616 - USD$23.03
50-day moving average USD$18.4204
200-day moving average USD$17.8309
Wall St. target price USD$30.22
PE ratio 7.6008
Dividend yield N/A (0%)
Earnings per share (TTM) USD$2.368

Buy Coherus BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Coherus BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Coherus BioSciences price performance over time

Historical closes compared with the close of $18.02 from 2020-11-16

1 week (2020-11-25) -0.17%
1 month (2020-11-06) 8.03%
3 months (2020-09-04) -2.22%
6 months (2020-06-05) -4.25%
1 year (2019-12-05) 2.56%
2 years (2018-12-04) 76.15%
3 years (2017-12-05) 112.00%
5 years (2015-12-04) -38.35%

Is Coherus BioSciences under- or over-valued?

Valuing Coherus BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Coherus BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Coherus BioSciences's P/E ratio

Coherus BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Coherus BioSciences shares trade at around 8x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Coherus BioSciences's EBITDA

Coherus BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$206.4 million.

The EBITDA is a measure of a Coherus BioSciences's overall financial performance and is widely used to measure a its profitability.

Coherus BioSciences financials

Revenue TTM USD$487.4 million
Operating margin TTM 41.68%
Gross profit TTM USD$244.9 million
Return on assets TTM 25.47%
Return on equity TTM 172.76%
Profit margin 37.11%
Book value $2.99
Market capitalisation USD$1.2 billion

TTM: trailing 12 months

Shorting Coherus BioSciences shares

There are currently 17.8 million Coherus BioSciences shares held short by investors – that's known as Coherus BioSciences's "short interest". This figure is 5.9% down from 18.9 million last month.

There are a few different ways that this level of interest in shorting Coherus BioSciences shares can be evaluated.

Coherus BioSciences's "short interest ratio" (SIR)

Coherus BioSciences's "short interest ratio" (SIR) is the quantity of Coherus BioSciences shares currently shorted divided by the average quantity of Coherus BioSciences shares traded daily (recently around 964900.43454644). Coherus BioSciences's SIR currently stands at 18.41. In other words for every 100,000 Coherus BioSciences shares traded daily on the market, roughly 18410 shares are currently held short.

However Coherus BioSciences's short interest can also be evaluated against the total number of Coherus BioSciences shares, or, against the total number of tradable Coherus BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Coherus BioSciences's short interest could be expressed as 0.25% of the outstanding shares (for every 100,000 Coherus BioSciences shares in existence, roughly 250 shares are currently held short) or 0.3067% of the tradable shares (for every 100,000 tradable Coherus BioSciences shares, roughly 307 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Coherus BioSciences.

Find out more about how you can short Coherus BioSciences stock.

Coherus BioSciences share dividends

We're not expecting Coherus BioSciences to pay a dividend over the next 12 months.

Coherus BioSciences share price volatility

Over the last 12 months, Coherus BioSciences's shares have ranged in value from as little as $10.8616 up to $23.03. A popular way to gauge a stock's volatility is its "beta".

CHRS.US volatility(beta: 1.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Coherus BioSciences's is 1.845. This would suggest that Coherus BioSciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Coherus BioSciences overview

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site